1. Torre LA, Siegel RL, Jemal A (2016) Lung cancer statistics. Adv Exp Med Biol 893:1–19

2. Novello S, Barlesi F, Califano R et al (2016) Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27:v1–v27

3. Carnio S, Novello S, Mele T, Levra MG, Scagliotti GV (2014) Extending survival of stage IV non-small cell lung cancer. Semin Oncol 41:69–92

4. Melosky B (2014) Treatment algorithms for patients with metastatic non-small cell, non-squamous lung cancer. Front Oncol 4:256

5. Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X (2015) Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 21:24–33

6. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264

7. Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639

8. Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135

9. Garon EB, Rizvi NA, Hui R et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018–2028

10. Fehrenbacher L, Spira A, Ballinger M et al (2016) Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387:1837–1846

11. Hellmann MD, Ciuleanu TE, Pluzanski A et al (2018) Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 378:2093–2104

12. Okamoto T, Maruyama R, Shoji F, Asoh H, Ikeda J, Miyamoto T, Nakamura T, Miyake T, Ichinose Y (2005) Long-term survivors in stage IV non-small cell lung cancer. Lung Cancer 47:85–91

13. Satoh H, Ishikawa H, Ohara G, Kagohashi K, Kurishima K, Ohtsuka M, Hizawa N (2007) Long-term survivors after chemotherapy in advanced non-small cell lung cancer. Anticancer Res 27:4457–4460

14. Dujon C, Azarian R, Petitpretz P (2009) Long-term survivors of advanced non-small-cell lung cancer: characterisation and prognostic factors in a retrospective study. Rev Mal Respir 26:952–960

15. Giroux Leprieur E, Lavole A, Ruppert AM, Gounant V, Wislez M, Cadranel J, Milleron B (2012) Factors associated with long-term survival of patients with advanced non-small cell lung cancer. Respirology 17:134–142

16. Van Damme V, Govaerts E, Nackaerts K, Dooms C, Wauters I, Vansteenkiste J (2013) Clinical factors predictive of long-term survival in advanced non-small cell lung cancer. Lung Cancer 79:73–76

17. Gettinger S, Horn L, Jackman D et al (2018) Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study. J Clin Oncol 36:1675–1684

18. National Cancer Institute (2017) Cancer Stat facts: lung and bronchus cancer. https://seer.cancer.gov/statfacts/html/lungb.html. Accessed 13 June 2017

19. Vokes EE, Ready N, Felip E et al (2018) Nivolumab versus docetaxel in previously treated advanced non-small cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol 29(4):959–965

20. Crino L, Bidoli P, Delmonte A et al (2016) Italian cohort of nivolumab Expanded Access Programme (EAP): preliminary data from a real-world population. J Clin Oncol 34:3067-

21. Leighl NB, Hellmann MD, Hui R, Carcereny E, Felip E, Ahn MJ, Eder JP (2017) KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab. J Clin Oncol 35:abst 9011

22. Herbst R, Garon E, Kim D-W et al (2017) KEYNOTE-010: durable clinical benefit in patients with previously treated, PD-L1-expressing NSCLC who completed pembrolizumab. J Thorac Oncol 12:S254–S255

23. Park K, Lewanski C, Gadgeel S et al. 3-year survival and duration of response in randomized phase ii study of atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR). J Thorac Oncol 12:S1840

24. Gadgeel S, Ciardiello F, Rittmeyer A et al (2017) OAK, a randomized Ph III study of atezolizumab vs docetaxel in patients with advanced NSCLC: results from subgroup analyses. J Thorac Oncol 12:S9–S10

25. Garassino M, Rizvi N, Besse B et al (2017) Atezolizumab as 1L therapy for advanced NSCLC in PD-L1—selected patients: updated ORR, PFS and OS data from the BIRCH study. J Thorac Oncol 12:S251–S252

26. Garassino MC, Cho BC, Kim JH et al (2018) Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol 19:521–536

27. Rittmeyer A, Barlesi F, Waterkamp D et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255–265

28. Abdel-Rahman O (2016) Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: a meta-analysis. Crit Rev Oncol Hematol 101:75–85

29. Aguiar PN Jr, Santoro IL, Tadokoro H, de Lima Lopes G, Filardi BA, Oliveira P, Mountzios G, de Mello RA (2016) The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. Immunotherapy 8:479–488

30. Brahmer J, Horn L, Jackman D, Spigel D, Scott A, Hellmann M, Powderly J (2017) Five-year follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC): clinical characteristics of long-term survivors. http://www.abstractsonline.com/pp8/#!/4292/presentation/12343. Accessed 13 June 2017

31. Mansfield AS, Dong H (2016) Implications of programmed cell death 1 ligand 1 heterogeneity in the selection of patients with non-small cell lung cancer to receive immunotherapy. Clin Pharmacol Ther 100:220–222

32. Ilie M, Long-Mira E, Bence C et al (2016) Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol 27:147–153

33. Mansfield AS, Aubry MC, Moser JC, Harrington SM, Dronca RS, Park SS, Dong H (2016) Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann Oncol 27:1953–1958

34. McLaughlin J, Han G, Schalper KA et al (2016) Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol 2:46–54

35. Teixido C, Karachaliou N, Gonzalez-Cao M, Morales-Espinosa D, Rosell R (2015) Assays for predicting and monitoring responses to lung cancer immunotherapy. Cancer Biol Med 12:87–95

36. Kumar R, Collins D, Dolly S, McDonald F, O’Brien MER, Yap TA (2017) Targeting the PD-1/PD-L1 axis in non-small cell lung cancer. Curr Probl Cancer 41:111–124

37. Govindan R, Ding L, Griffith M et al (2012) Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150:1121–1134

38. de Bruin EC, McGranahan N, Mitter R et al (2014) Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346:251–256

39. McGranahan N, Furness AJ, Rosenthal R et al (2016) Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351:1463–1469

40. Carbone DP, Reck M, Paz-Ares L et al (2017) First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med 376:2415–2426

41. Gandara DR, Kowanetz M, Mok TSK et al (2017) Blood-based biomarkers for cancer immunotherapy: tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L + NSCLC (POPLAR and OAK). Ann Oncol 28:1295O

42. Hellmann MD, Nathanson T, Rizvi H et al (2018) Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer. Cancer Cell 33:843 e4–852 e4

43. Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509–2520

44. Rizvi NA, Hellmann MD, Snyder A et al (2015) Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124–128

45. Schrock A, Sharma N, Peled N et al (2017) Updated dataset assessing tumor mutation burden (TMB) as a biomarker for response to PD-1/PD-L1 targeted therapies in lung cancer (LC). J Thorac Oncol 12:S422

46. Scilla KA, Bentzen SM, Lam VK et al (2017) Neutrophil-lymphocyte ratio is a prognostic marker in patients with locally advanced (Stage IIIA and IIIB) non-small cell lung cancer treated with combined modality therapy. Oncologist 22:737–742

47. Labomascus S, Fughhi I, Bonomi P, Fidler MJ, Borgia JA, Basu S, Hoch MA, Batus M (2017) Neutrophil to lymphocyte ratio as predictive of prolonged progression free survival (PFS) and overall survival (OS) in patients with metastatic non-small cell lung cancer (NSCLC) treated with second-line PD-1 immune checkpoint inhibitors. J Clin Oncol 35:e14530-e

48. Bagley SJ, Kothari S, Aggarwal C et al (2017) Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer 106:1–7

49. Zer A, Sung MR, Walia P et al (2018) Correlation of neutrophil to lymphocyte ratio and absolute neutrophil count with outcomes with PD-1 axis inhibitors in patients with advanced non-small-cell lung cancer. Clin Lung Cancer 19(5):426–434.e1. https://doi.org/10.1016/j.cllc.2018.04.008

50. Lee CK, Man J, Lord S, Links M, Gebski V, Mok T, Yang JC (2017) Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer—a meta-analysis. J Thorac Oncol 12:403–407

51. Ardizzoni A, Bidoli P, Chiari R et al (2017) Nivolumab in advanced non-squamous NSCLC patients with KRAS mutations: results from the italian expanded access program (EAP). J Thorac Oncol 12:S1804

52. Gettinger S, Choi J, Mani N et al (2017) Predictive value of measuring somatic mutations and tumor infiltrating lymphocytes for PD-1 axis therapy in non-small cell lung cancer (NSCLC). J Thorac Oncol 12:S430–S431

53. Olugbile S, Bao R, Hensing T, Nakamura Y, Vokes E (2017) Molecular determinants of lack of tumor immune infiltration in NSCLC. J Thorac Oncol 12:S431–S432

54. Tumeh PC, Harview CL, Yearley JH et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568–571

55. Sanmamed MF, Perez-Gracia JL, Schalper KA et al (2017) Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small cell lung cancer patients. Ann Oncol 28:1988–1995

56. Blank CU, Haanen JB, Ribas A, Schumacher TN (2016) Cancer Immunology. The “cancer immunogram”. Science 352:658–660

57. Mezquita L, Auclin E, Ferrara R et al (2018) Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol 4:351–357

58. Park W, Kwon D, Saravia D et al (2018) Developing a predictive model for clinical outcomes of advanced non-small cell lung cancer patients treated with nivolumab. Clin Lung Cancer 19:280–288 e4

59. Costa R, Carneiro BA, Agulnik M, Rademaker AW, Pai SG, Villaflor VM, Cristofanilli M, Sosman JA, Giles FJ (2017) Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. Oncotarget 8:8910–8920

60. Cousin S, Italiano A (2016) Molecular pathways: immune checkpoint antibodies and their toxicities. Clin Cancer Res 22:4550–4555

61. Horvat TZ, Adel NG, Dang TO et al (2015) Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center. J Clin Oncol 33:3193–3198

62. Weber JS, Hodi FS, Wolchok JD et al (2017) Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 35:785–792

63. Leighl N, Gandhi L, Hellmann M et al (2015) Pembrolizumab for NSCLC: immune-mediated adverse events and corticosteroid use. J Thorac Oncol 10:S233

64. Martínez Bernal G, Mezquita L, Auclin E et al (2017) Baseline corticosteroids (CS) could be associated with absence of benefit to immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients. Ann Oncol 28:1323

65. Zhang T, Xie J, Arai S et al (2016) The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. Oncotarget 7:73068–73079

66. Pillai R, Behera M, Owonikoko T, Kamphorst A, Pakkala S, Belani C, Khuri F, Ahmed R, Ramalingam S (2017) Evaluation of toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer (NSCLC). J Thorac Oncol 12:S253–S254

67. Downey SG, Klapper JA, Smith FO et al (2007) Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 13:6681–6688

68. Schadendorf D, Larkin J, Postow M, Chiarion-Sileni V, Gonzalez R, Rutkowski P (2016) Efficacy and safety outcomes in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity. In: 12th Congress of the European Association of Dermato Oncology, August 31-September 3, 2016; Vienna, Austria

69. Hua C, Boussemart L, Mateus C et al (2016) Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 152:45–51

70. Sanlorenzo M, Vujic I, Daud A et al (2015) Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol 151:1206–1212

71. Osorio JC, Ni A, Chaft JE et al (2017) Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 28:583–589

72. von Pawel J, Syrigos K, Mazieres J et al (2017) Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the phase III study OAK. Ann Oncol 28:1314P

73. Haratani K, Hayashi H, Chiba Y et al (2017) Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol

74. Melero I, Berman DM, Aznar MA, Korman AJ, Perez Gracia JL, Haanen J (2015) Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer 15:457–472

75. Marshall R, Popple A, Kordbacheh T, Honeychurch J, Faivre-Finn C, Illidge T (2017) Immune checkpoint inhibitors in lung cancer—an unheralded opportunity? Clin Oncol (R Coll Radiol) 29:207–217

76. Gerber DE, Urbanic JJ, Langer C et al (2017) Treatment design and rationale for a randomized trial of cisplatin and etoposide plus thoracic radiotherapy followed by nivolumab or placebo for locally advanced non-small-cell lung cancer (RTOG 3505). Clin Lung Cancer 18:333–339

77. Zitvogel L, Kepp O, Kroemer G (2011) Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 8:151–160

78. Rizvi NA, Hellmann MD, Brahmer JR et al (2016) Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 34:2969–2979

79. Juergens R, Hellmann M, Brahmer J et al (2017) First-line nivolumab plus platinum-based doublet chemotherapy for advanced NSCLC: checkmate 012 3-year update. J Thorac Oncol 12:S1792–S1793

80. Langer CJ, Gadgeel SM, Borghaei H et al (2016) Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 17:1497–1508

81. Borghaei H, Langer CJ, Gadgeel S et al (2017) Updated results from KEYNOTE-021 cohort G: a randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC. Ann Oncol 28:LBA49

82. Gandhi L, Rodriguez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078–2092

83. Paz-Ares LG, Luft A, Tafreshi A et al (2018) Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) nonsmall cell lung cancer (NSCLC). American Society of Clinical Oncology, Chicago

84. Liu SV, Powderly JD, Camidge DR et al (2015) Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 33:8030-

85. Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23–34

86. Hellmann MD, Rizvi NA, Goldman JW et al (2017) Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol 18:31–41

87. Goldman JW, Antonia S, Gettinger S et al (2017) Nivolumab plus ipilimumab as first-line treatment for advanced NSCLC: 2-year overall survival and long-term outcomes from checkmate 012. J Clin Oncol 35:Abstr 9093

88. Gubens MA, Sequist LV, Stevenson J et al (2016) Phase I/II study of pembrolizumab (pembro) plus ipilimumab (ipi) as second-line therapy for NSCLC: KEYNOTE-021 cohorts D and H. J Clin Oncol 34:9027-

89. Antonia S, Goldberg SB, Balmanoukian A et al (2016) Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol 17:299–308